Floatz logo

Ipilimumab

Colorectal Cancer Metastatic

GERCOR - Multidisciplinary Oncology Cooperative Groupmonoclonal_antibodyPhase 2Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
65/ 100

Competitive context

64 Active assets in the Colorectal Cancer Metastatic cohort.

Asset / SponsorPhaseRating
Binimetinib
Pierre Fabre Medicament
Phase 3BB
Irinotecan
Oncolytics Biotech
Phase 4BB
Aflibercept
Sanofi
Phase 3BB
Inno-206
Northwell Health
Phase 4B
Durvalumab
University of Iowa
Phase 2B

View all 50 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →